![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: POU2F2 |
Gene summary for POU2F2 |
![]() |
Gene information | Species | Human | Gene symbol | POU2F2 | Gene ID | 5452 |
Gene name | POU class 2 homeobox 2 | |
Gene Alias | OCT2 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | P09086 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5452 | POU2F2 | ATC09 | Human | Thyroid | ATC | 2.71e-04 | 2.47e-01 | 0.2871 |
5452 | POU2F2 | ATC12 | Human | Thyroid | ATC | 1.66e-47 | 8.89e-01 | 0.34 |
5452 | POU2F2 | ATC13 | Human | Thyroid | ATC | 1.49e-15 | 2.24e-01 | 0.34 |
5452 | POU2F2 | ATC3 | Human | Thyroid | ATC | 5.17e-07 | 6.64e-01 | 0.338 |
5452 | POU2F2 | ATC4 | Human | Thyroid | ATC | 6.21e-51 | 1.07e+00 | 0.34 |
5452 | POU2F2 | ATC5 | Human | Thyroid | ATC | 8.44e-14 | 2.46e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
GO:009858615 | Thyroid | ATC | cellular response to virus | 44/6293 | 84/18723 | 2.94e-04 | 1.87e-03 | 44 |
GO:000181924 | Thyroid | ATC | positive regulation of cytokine production | 189/6293 | 467/18723 | 1.00e-03 | 5.31e-03 | 189 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POU2F2 | SNV | Missense_Mutation | c.1122C>A | p.Ser374Arg | p.S374R | P09086 | protein_coding | deleterious(0) | possibly_damaging(0.806) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
POU2F2 | SNV | Missense_Mutation | rs200445754 | c.1151N>T | p.Ala384Val | p.A384V | P09086 | protein_coding | tolerated(0.54) | benign(0.15) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POU2F2 | SNV | Missense_Mutation | c.674N>A | p.Gly225Asp | p.G225D | P09086 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A0AB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
POU2F2 | SNV | Missense_Mutation | c.1271N>A | p.Gly424Glu | p.G424E | P09086 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.986) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
POU2F2 | deletion | Frame_Shift_Del | novel | c.1183delN | p.Ser395ValfsTer2 | p.S395Vfs*2 | P09086 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
POU2F2 | SNV | Missense_Mutation | c.74A>G | p.Asp25Gly | p.D25G | P09086 | protein_coding | deleterious(0.03) | possibly_damaging(0.534) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD | |
POU2F2 | SNV | Missense_Mutation | c.1138N>T | p.Pro380Ser | p.P380S | P09086 | protein_coding | tolerated(1) | benign(0.026) | TCGA-AA-3955-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | capecitabine | CR | |
POU2F2 | SNV | Missense_Mutation | novel | c.931N>A | p.Ala311Thr | p.A311T | P09086 | protein_coding | tolerated(0.37) | probably_damaging(0.995) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
POU2F2 | SNV | Missense_Mutation | rs761554246 | c.799N>A | p.Asp267Asn | p.D267N | P09086 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
POU2F2 | SNV | Missense_Mutation | c.49N>A | p.Leu17Met | p.L17M | P09086 | protein_coding | tolerated(0.17) | probably_damaging(0.979) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5452 | POU2F2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | LINAGLIPTIN | LINAGLIPTIN | 23073734 |
Page: 1 |